Similarly, Perez et al found that addition of dasatinib to fluoruracil and oxalplatin re-sensitize CRC tumors that expressed high levels of p-SRC [36] Biomarker driven data will likely determine the future of Src inhibitors in combination with chemotherapy for the treatment of solid tumors. Here, SRC is linked to colorectal carcinoma.